ACIP vice chair has even publicly accused FDA Commissioner Marty Makary of blocking or stalling efforts to pull the vaccines off the market. According to reports from that time period, ACIP members ...

In today’s Pharmaceutical Executive Daily, the FDA reportedly removes its two-study requirement for new drug approvals, Hims ...

Crohn’s patients taking Omvoh saw three-years of remission when taking Omvoh, according to new long-term data released by Eli Lilly. 1 The data is the result of the Phase 3 VIVID-2 open label ...

Hims & Hers has agreed to acquire Australia-based Eucalyptus for up to $1.15 billion, expanding its international footprint ...

Discover how access barriers evolve across the biopharma brand lifecycle, from launch to loss of exclusivity, and how to address them proactively. Learn how data-driven insights and affordability ...

FDA Will Drop Two-Study Requirement for New Drug Approvals, Aiming to Speed Access U.S News February 18, 2026 ...

In today’s Pharmaceutical Executive Daily, the FDA begins reviewing Moderna’s seasonal flu vaccine under a revised regulatory approach, Eli Lilly signs a $100 million licensing agreement with CSL for ...

The broader Miami-Fort Lauderdale-West Palm Beach metro produced $533.7 billion in GDP in 2023, a nearly 9% year-over-year ...

Exclusive licensing grants Lilly development and commercialization rights for clazakizumab beyond ESKD-related cardiovascular prevention, while CSL retains the ESKD cardiovascular events indication.

On the heels of a Type A meeting with FDA’s Center for Biologics and Research (CBER), Moderna’s seasonal influenza vaccine ...

This article explores best practices for modernizing the healthcare supply chain by balancing fiscal responsibility with patient safety requirements. It highlights how advanced technologies such as ...

This eBook highlights Werner’s premium and expedited shipping solutions designed specifically to address the high-stakes requirements of the $1.6 trillion global pharmaceutical industry. It details ...